Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Ribavirin for Viral Hemorrhagic Fever
NCT02483260Suspended
- Sponsor
- U.S. Army Medical Research and Development Command
- Start
- Jun 2016
- Primary completion
- Oct 2027
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Open-label, single-arm trial of ribavirin in Crimean–Congo hemorrhagic fever (CCHF) and Lassa fever, sponsored by U.S. Army Medical Research and Development Command. Primary endpoint: Adverse reactions at 5 years. Started Jun 2016; status: suspended.
02
Drugs
ribavirin
03
Conditions
Crimean–Congo hemorrhagic fever (CCHF)Lassa fever
Beyond the preview
Go deeper on NCT02483260.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483260.